News und Analysen
NANOBIOTIX Announces Pricing of Global Offering and Approval to List on NASDAQ Global Select Market
Regulatory News:
NANOBIOTIX (Paris:NANO) (Euronext: NANO – ISIN : FR0011341205 – the ‘‘Company’’), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer
Pfizer and BioNTech Receive FDA Advisory Committee Vote Supporting Potential First Emergency Use Authorization for Vaccine to Combat COVID-19 in the U.S.
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted
Quidel Corporation CEO Douglas Bryant Named Executive of the Year in MedTech Dive Awards For 2020
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel’s
GenSight Biologics Announces the Partial Conversion of Convertible Bonds and Full Exercise of Share Warrants by Kreos Capital
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (Paris:SIGHT) (the "Company" or "GenSight"), a biopharma company focused on developing and
Pfizer and BioNTech Announce Publication of Results from Landmark Phase 3 Trial of BNT162b2 COVID-19 Vaccine Candidate in The New England Journal of Medicine
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the New England Journal of Medicine has published safety and final efficacy results from the pivotal Phase 3 trial of
Humana Announces New Primary Care Value-Based Model
Leading health and well-being company Humana Inc. (NYSE: HUM) today announced an expansion of its value-based program portfolio with the forthcoming launch of the Primary Care First (PCF) model. It
Savara Provides Pipeline and Business Update
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today provided an update on changes to the Company’s pipeline, leadership, and business operations that are being taken to improve
Waters Corporation Appoints Pearl S. Huang to Board of Directors
Waters Corporation (NYSE:WAT) today announced that Dr. Pearl S. Huang, President and CEO of Cygnal Therapeutics and venture partner at Flagship Pioneering, has been appointed as a Director of
First Patient Enrolled in Novocure’s Global Phase 3 TRIDENT Trial of Optune® Concurrent with Radiation Therapy in Newly Diagnosed Glioblastoma
Novocure (NASDAQ: NVCR) today announced the first patient has been enrolled in its global phase 3 TRIDENT trial, a randomized study in newly diagnosed glioblastoma (GBM) testing the potential
GenSight Biologics Announces Publication of Results from LUMEVOQ® REVERSE Pivotal Phase III Trial and Non-Human Primate Study in Science Translational Medicine
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies
NANOBIOTIX Announces the Filing of an Amended Registration Statement, Including an Estimated Initial Public Offering Range
Regulatory News:
NANOBIOTIX (Paris:NANO) (Euronext: NANO – ISIN : FR0011341205 – the ‘‘Company’’), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer
Puma Biotechnology Presents Final Overall Survival Analysis from the Phase III ExteNET Trial at the 2020 SABCS
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that efficacy results of neratinib in HER2-positive early stage breast cancer (eBC) from the Phase III ExteNET trial
Puma Biotechnology Presents Updated Results from the Phase II SUMMIT Trial of Neratinib for HER2-Mutant, HR-Positive Metastatic Breast Cancer at SABCS 2020
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, presented updated results from the ongoing Phase II SUMMIT trial of neratinib at the 2020 Virtual San Antonio Breast Cancer
Lantheus Holdings Announces Acceptance and Priority Review of New Drug Application for PyLTM (18F-DCFPyL), a PSMA-Targeted Prostate Cancer PET Imaging Agent
Lantheus Holdings, Inc. (NASDAQ: LNTH) (the Company), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture
Huntington’s St. Mary’s Medical Center and Humana Announce Medicare Network Agreement
St. Mary’s Medical Center, one of West Virginia’s largest health care facilities, and leading health and well-being company Humana Inc. (NYSE: HUM) announced today they have signed an agreement to
Acadia Healthcare Forms Joint Venture with Henry Ford Health System to Build Modern Behavioral Health Facility to Serve Detroit Area Communities
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it has formed a joint venture with Henry Ford Health System, one of Michigan’s premier, academic and integrated health systems
PyL™ (18F-DCFPyL), Lantheus’ PSMA-Targeted Prostate Cancer Imaging Agent, to be Used in POINT Biopharma’s PSMA-Targeted Radioligand Therapeutic Phase 3 Trial in Patients with Metastatic Castration Resistant Prostate Cancer
Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., a global leader in the development, manufacture and
Charles River Delivers Industry-First Deciphex Patholytix Digital Pathology Peer Review for GLP Studies
Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it is the first company to offer clients Good Laboratory Practices (GLP) validated digital peer review using Deciphex
NanoString’s GeoMx Digital Spatial Profiler Identifies Diverse Immune Responses Within COVID-19 Patients in Study Published in Nature Communications
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced the publication of a new peer-reviewed study
Simbec-Orion rationalisiert Studiendurchführung mit klinischen Anwendungen von Veeva
Veeva Systems (NYSE: VEEV) gab heute bekannt, dass Simbec-Orion, eine auf klinische Pharmakologie, Onkologie und seltene Krankheiten spezialisierte Full-Service-Vertragsforschungsorganisation
Waters Collaborates with Dr. Sunghwan Kim of Kyungpook National University to Advance Precision Analysis of Complex Chemical Compounds
Waters Corporation (NYSE:WAT) has formally expanded its long-standing, collaborative relationship with Dr. Sunghwan Kim of Kyungpook National University to further explore the use of Waters’
U.S. FDA Accepts for Priority Review the Biologics License Application for Pfizer’s Investigational 20-valent Pneumococcal Conjugate Vaccine for Adults 18 Years of Age and Older
Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for priority review a Biologics License Application (BLA) for its 20-valent pneumococcal conjugate
Illumina and Harvard Pilgrim Health Care Expand Access to Whole-Genome Sequencing for Genetic Disease Testing
Illumina, Inc. (Nasdaq: ILMN) and Harvard Pilgrim Health Care announce a risk-sharing agreement to make whole-genome sequencing (WGS) available to certain Harvard Pilgrim members, effective January
Simbec-Orion Streamlines Trial Execution with Veeva Clinical Applications
Veeva Systems (NYSE: VEEV) today announced that Simbec-Orion, a full-service contract research organization (CRO) specialized in clinical pharmacology, oncology, and rare diseases, is adopting
Simbec-Orion Streamlines Trial Execution With Veeva Clinical Applications
Veeva Systems (NYSE: VEEV) today announced that Simbec-Orion, a full-service contract research organization (CRO) specialized in clinical pharmacology, oncology, and rare diseases, is adopting